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Abstract
Mitochondrial DNA (mtDNA) copy number in peripheral blood is associated with increased risk of several cancers. However,
data from prospective studies on mtDNA copy number and breast cancer risk are lacking. We evaluated the association
between mtDNA copy number in peripheral blood and breast cancer risk in a nested case-control study of 183 breast cancer
cases with pre-diagnostic blood samples and 529 individually matched controls among participants of the Singapore
Chinese Health Study. The mtDNA copy number was measured using real time PCR. Conditional logistic regression analyses
showed that there was an overall positive association between mtDNA copy number and breast cancer risk (Ptrend = 0.01).
The elevated risk for higher mtDNA copy numbers was primarily seen for women with ,3 years between blood draw and
cancer diagnosis; ORs (95% CIs) for 2nd, 3rd, 4th, and 5th quintile of mtDNA copy number were 1.52 (0.61, 3.82), 2.52 (1.03,
6.12), 3.12 (1.31, 7.43), and 3.06 (1.25, 7.47), respectively, compared with the 1st quintile (Ptrend = 0.004). There was no
association between mtDNA copy number and breast cancer risk among women who donated a blood sample $3 years
before breast cancer diagnosis (Ptrend = 0.41). This study supports a prospective association between increased mtDNA copy
number and breast cancer risk that is dependent on the time interval between blood collection and breast cancer diagnosis.
Future studies are warranted to confirm these findings and to elucidate the biological role of mtDNA copy number in breast
cancer risk.
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Introduction
Breast cancer is the most common cancer among women in the
United States and accounts for 29% of all cancers in women with
approximately 226,870 new cases expected to occur in 2012 [1].
The incidence of breast cancer is also rapidly increasing in several
Asian populations and breast cancer is one of the most frequently
diagnosed cancers in women worldwide [2]. Although early
detection using mammography and improved treatments for
invasive breast cancers have significantly reduced morbidity and
mortality due to breast cancer, the malignancy remains the second
leading cause of cancer death among women in the United States
[1] and remains an important cause of cancer related deaths in
women around the world [2].
Mitochondria, whose principal function is to generate energy
through aerobic respiration, are the major source and target of
intracellular reactive oxygen species (ROS) that plays an important
role in breast carcinogenesis [3,4]. Each cell has multiple copies of
mitochondria and each mitochondrion has 2–10 copies of the
mitochondrial genome [5,6]. The amount of mitochondrial DNA
(mtDNA) remains relatively stable within the cells under physio-
logical conditions [5,7]. As reviewed by Radppour et al, several
studies have found somatic mitochondrial mutations and deletions
in breast tumor tissue, suggesting that changes in mtDNA may
play a significant role in breast carcinogenesis [8]. This hypothesis
has been supported by epidemiological studies that demonstrated a
statistically significant association between increasing mtDNA
copy number in peripheral blood and increased risk of breast
cancer [9] as well as other malignancies including Non-Hodgkin
lymphoma [10], lung cancer [11], pancreatic cancer [12], and
colorectal cancer [13,14]. However, other studies showed different
results. A retrospective case-control study showed decreased
mtDNA copy number associated with increased breast cancer
risk [15]. One recent prospective study found no association
between mtDNA copy number and gastric cancer [16] while two
retrospective case-control studies showed an increased risk of renal
cancer associated with decreased mtDNA copy number [17,18].
Given that the development of and treatment for cancer can cause
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oxidative stress, which could impact mtDNA copy number, a
prospectively designed study with blood samples collected many
years prior to cancer diagnosis could overcome this potential
problem. Therefore we conducted a nested case-control study
within the Singapore Chinese Health Study (SCHS) using blood
samples that were collected from the cohort participants before
breast cancer diagnosis. The present study allowed us to evaluate
the association between mtDNA copy number and the risk of
breast cancer in pre-diagnostic peripheral blood samples.
Materials and Methods
Study Population
The study participants were chosen from the Singapore Chinese
Health Study (SCHS), a population-based prospective cohort of
63,257 Chinese women and men from two major dialect groups,
the Hokkiens and Cantonese, aged 45–74 years who were enrolled
in the study from April 1993 through December 1998 [19]. The
participants lived in government housing estates that were home to
86% of the Singapore population. At recruitment, a trained
interviewer used a structured questionnaire to conduct a face-to-
face interview in the participant’s home and collected information
Table 1. Demographic and reproductive characteristics of breast cancer patients and control women, the Singapore Chinese
Health Study.
Cases (%) Controls (%) P
(n = 183) (n =529)
Age at sample collection (mean 6 SD) 61.168.3 61.168.1 0.96
Dialect group
Cantonese 54.6 53.7
Hokkien 45.4 46.3 0.82
Highest level of education
No formal education 22.4 30.4
Primary school 47.5 41.8
Secondary school or higher 30.1 27.8 0.11
Body mass index (kg/m2)
,20 10.9 12.5
20 to ,24 50.3 52.2
24 to ,28 26.8 27.6
28+ 12.0 7.7 0.36
Age at menarche (years)
,13 14.2 17.4
13–14 48.6 37.6
15–16 29.5 34.6
17+/never became regular 7.7 10.4 0.07
Number of live births
0 12.6 7.2
1–2 36.1 30.0
3–4 30.0 41.4
5+ 21.3 21.4 0.01
Menopause status at sample collection
Pre-menopause 11.5 11.0
Post-menopause 88.5 89.0 0.85
Use of hormone replacement therapy
No 92.4 93.8
Yes 7.6 6.2 0.51
Weekly vigorous or strenuous physical activity
No 94.0 94.1
Yes 6.0 5.9 0.94
Family history of breast cancer*
No 98.4 98.5
Yes 1.6 1.5 0.90
*Family history of breast cancer among first degree relatives.
doi:10.1371/journal.pone.0065968.t001
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on demographics, tobacco use, physical activity, menstrual/
reproductive history in women, medical history, and family
history of cancer. A 165-item food frequency questionnaire was
validated against a series of 24-hour dietary recall interviews was
used to collect information on diet and alcohol use [19].
Blood and single-void urine specimens were requested from
subjects drawn from a 3% random sample of enrollees in April
1994. All surviving members of the cohort were contacted to
provide a biospecimen between January 2000 and April 2005 and
biospecimens were obtained from more than 32,500 participants.
This study was approved by the Institutional Review Boards of the
National University of Singapore, University of Pittsburgh, and
the University of Minnesota and written informed consent was
obtained from all participants.
Cases: The population-based cancer registry in Singapore was
used to identify the incident breast cancer cases [20]. Only cohort
participants who donated a blood sample between January 2000
and April 2005 and developed breast cancer as of December 31,
2007 were included in the present study. In total, 183 breast
cancer patients, whose diagnosis were confirmed by manual
reviews of clinical/pathology reports and who provided a blood
sample before their development of breast cancer were included in
the present analysis.
Controls: For each case, 3 control women were randomly selected
among the cohort participants of the Singapore Chinese Health
Study who donated a blood sample between January 2000 and
April 2005 and were alive and remained free of cancer on the date
of breast cancer diagnosis of the index case, The control women
were individually matched with the breast cancer cases with
respect to age at baseline interviews (63 years), date of baseline
interview (62 years), dialect group (Cantonese vs. Hokkien),
menopausal status at sample collection and date of biospecimen
collection (66 months). In total, 529 women who met these
criteria were chosen as a comparison control group.
Laboratory Methods
All DNA samples were extracted from 0.5 ml of buffy coat
fraction of the whole blood using the QiaAMP 96 DNA blood kits
(Qiagen Inc., Gaithersburg, MD, USA). DNA samples of 183
breast cancers and 529 individually matched controls were
retrieved from the biorepository of the Singapore Chinese Health
Study. All DNA samples of a given matched set (containing the
samples from the case and the three matched controls) were
arranged in random order, identified only by unique codes, and
tested in the same batch of laboratory assay for mitochondrial
DNA (mtDNA) copy number. The details of the mtDNA copy
number assay have been described previously [14]. MtDNA copy
number was measured using a real time quantitative polymerase
chain reaction (PCR) using an Applied Biosystems 7900 Sequence
Detection System (Applied Biosystems, Foster City, CA). One
primer pair specific for the mitochondrial DNA (ND1) and another
primer pair specific for the nuclear DNA (18s) were designed for
relative quantification for mtDNA copy number. The primer
sequences for the mitochondrial ND1 gene were: forward primer
(ND1-F), 59- CCCTAAAACCCGCCACATCT-39; reverse prim-
er (ND1-R), 59-GAGCGATGGTGAGAGCTAAGGT-39. The
primer pair used for the amplification of the nuclear gene 18s was
as follows: forward primer (18s-F), 59-TAGAGGGA-
CAAGTGGCGTTC-39; reverse primer (18s-R), 59-
CGCTGAGCCAGTCAGTGT-39. Standard curves made by
serial dilution of a reference DNA sample was used to determine
the ratio of mtDNA copy number to the amount of nuclear DNA
that is proportional to the mtDNA copy number in each cell. All
samples were assayed in duplicate. A calibrator DNA (i.e. genomic
DNA from a healthy control volunteer) was used to standardize
analytical variation between different mtDNA copy number assay
runs. The 14 mL PCR mixture contained 16 SYBR Green
mastermix (Applied Biosystems; Foster City, CA, USA), 215 nM
ND1-R (or 18s-R) primer, 215 nM ND1-F (or 18s-F) primer, and
0.4 ng of genomic DNA for ND1 and 18s. The thermal cycling
conditions were 95uC for 10 minutes, followed by 40 cycles of
95uC for 15 seconds, and 60uC for 1 minute for ND1 and 62uC for
1 minute for 18s. The efficiency of all quantitative PCR runs
ranged from 99% to 110%.The R2 for all standard curves was
$0.99. Standard deviations for the cycle of threshold (Ct)
duplicates were #0.25. Based on analyses of 27 blinded duplicate
samples analyzed on two different days the coefficient of variation
(CV) was 14%.
Statistical Analyses
All statistical analyses were carried out using SAS software
version 9.1.3 (SAS Institute, Cary, NC). The distribution of the
relative mtDNA copy number (i.e. the ratio of mtDNA to nuclear
DNA in the study samples normalized to a reference DNA sample)
was markedly skewed toward high values and corrected to a large
extent by transformation to logarithmic values. Therefore, all
statistical tests were performed on logarithmically transformed
values, and geometric means are presented. The x2 test and the t-
test were used to compare the distributions of demographics,
lifestyle and reproductive characteristics between breast cancer
cases and controls. Pearson correlation coefficient was used to
evaluate the correlation between mtDNA copy number and time
interval between blood collection and breast cancer diagnosis.
Differences in the relative mtDNA copy number across different
groups of selected reproductive characteristics among control
participants were examined using analysis of covariance (AN-
COVA). These analyses were adjusted for age and analytical run
in which mtDNA copy number was measured (batch number) to
control for variation in relative mtDNA copy number across
Table 2. Geometric means of relative mtDNA number by
selected reproductive variables among controls only, the
Singapore Chinese Health Study.
No Mean* (95% CI) P
Age at menarche (years)
,13 92 2.18 (1.94, 2.44)
13–14 199 2.12 (1.98, 2.30)
15–16 183 2.10 (1.94, 2.26)
17+/never became regular 55 2.12 (1.84, 2.46) 0.68
Number of live births
0 38 2.04 (1.72, 2.42)
1–2 159 2.14 (1.96, 2.34)
3–4 219 2.18 (2.02, 2.32)
5+ 113 2.04 (1.82, 2.26) 0.87
Menopause status at sample collection
Pre-menopause 58 2.14 (1.84, 2.48)
Post-menopause 471 2.12 (2.02, 2.24) 0.91
Use of hormone replacement therapy
No 496 2.12 (2.02, 2.22)
Yes 33 2.22 (1.86, 2.66) 0.59
*Adjusted for age at sample collection and batch number of laboratory assays.
doi:10.1371/journal.pone.0065968.t002
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different analytical runs. Conditional logistic regression models
retaining original matched sets that controlled for matching factors
and the laboratory batches for mtDNA assays were used to
evaluate the association between relative mtDNA copy number
and breast cancer risk after adjustment for body mass index (BMI),
age at menarche and number of live birth. The study participants
were grouped into quintiles according to the distribution of relative
mtDNA copy number among control subjects. Additional
subgroup analyses for the mtDNA-breast cancer risk were
performed using conditional logistic regression models according
to the time interval between blood sample collection and breast
cancer diagnosis ($3 years vs.,3 years) and breast cancer stage at
the time of diagnosis. All P-values ,0.05 were considered to be
statistically significant.
Results
Women with breast cancer were more likely to be nulliparous or
have fewer live births as compared to control women (Table 1).
Compared to controls, cases were also more educated, had earlier
age at menarche (#14 years), and more likely to have BMI
$28 kg/m2 or use hormone replacement therapy, although these
differences did not reach statistical significance (Table 1). The
relative mtDNA copy number was not associated with any of the
reproductive variables such as age at menarche, menopausal
status, use of hormone replacement therapy and number of live
births (p.0.05) among control women (Table 2).
After adjustment for age at menarche, BMI and number of live
births, relative mtDNA copy number was positively associated
with breast cancer risk overall (p for trend= 0.01) (Table 3).
Additional analyses evaluating the association between the relative
mtDNA copy number and risk of incident breast cancer stratified
by time interval between blood sample collection and breast
cancer diagnosis showed that relative mtDNA copy number was
associated with breast cancer risk only among those women from
whom a blood sample was collected within 3 years of breast cancer
diagnosis. Relative mtDNA copy number was negatively correlat-
ed with time to breast cancer diagnosis (r =20.15; p = 0.048).
Among women who donated a blood sample ,3 years prior to
breast cancer diagnosis, ORs (95% CIs) of breast cancer for
women in the 2nd, 3rd, 4th, and 5th quintiles of mtDNA copy were
1.52 (0.61, 3.82), 2.52 (1.03, 6.12), 3.12 (1.31, 7.43), and 3.06
(1.25, 7.47), respectively, compared with the 1st quintile (p for
trend= 0.004) (Table 3). In contrast, there was no association
between mtDNA copy number and breast cancer risk among
women who donated a blood sample $3 years prior to breast
cancer diagnosis (p for trend= 0.41) (Table 3).
Discussion
This is the first study to demonstrate a prospective association
between increased relative mtDNA copy number and increased
breast cancer risk. The findings from the current study are in
agreement with the findings from an earlier retrospective case-
control study (100 breast cancer cases and 100 controls in a
predominantly white population) [9]. However, these results are
contradictory to another case-control study (60 breast cancer cases
and 50 controls in a Chinese population) that showed decreased
mtDNA copy number was associated with increased breast cancer
risk [15]. Several other studies have shown mixed associations
between mtDNA copy number and risk of several other cancers.
One retrospective case-control study has shown an association
between increased mtDNA copy number and increased risk of
colorectal cancer [13] while other retrospective studies have shown
an association between decreased mtDNA copy number in
peripheral blood and increased risk of renal cancers [17,18].
Three prospective studies from the Alpha-tocopherol, beta-
carotene and cancer prevention (ATBC) study showed increased
mtDNA copy number to be associated with increased risk of
cancers in the lung [11], pancreas [12] and NHL [10]. Another
prospective study from the Shanghai women’s cohort showed no
association between mtDNA copy number and gastric cancer [16]
while the Singapore Chinese Health Study showed a U shaped
association between mtDNA copy number and colorectal cancer
risk [14].
This study found that mtDNA copy number was negatively
correlated with the time between blood draw and breast cancer
diagnosis, and that the association between relative mtDNA copy
number and breast cancer risk was restricted only to those women
who donated a blood sample within 3 years of breast cancer
diagnosis. A previous case-control study by Xia et al showed the
stage I breast cancers had a lower mtDNA copy number in
peripheral blood while stage II–IV breast cancers had increased
mtDNA copy number in peripheral blood [15]. This finding along
with the discrepant association between mtDNA copy number in
peripheral blood and breast cancer risk observed in the two case-
control studies suggest that breast cancer itself may modify that
levels of mtDNA observed in peripheral blood and highlights the
need for prospective study designs, such as the present study, to
evaluate the association between mtDNA copy number in
Table 3. The relative mtDNA copy number in relation to risk of breast cancer, the Singapore Chinese Health Study.
Time interval between blood draw
and cancer diagnosis mtDNA copy number in quintiles
1st quintile 2nd quintile 3rd quintile 4th quintile 5th quintile
(,1.50) (1.50–1.94) (1.95–2.51) (2.52–3.38) (.3.38) P for trend
All subjects Cases/Controls 29/117 27/109 38/95 46/102 43/106
OR{ (95%CI) 1.00 1.03 (0.56, 1.90) 1.70 (0.96, 3.01) 1.96 (1.12, 3.44) 1.75 (0.97, 3.15) 0.010
,3 years` Cases/Controls 11/63 13/50 17/41 24/51 23/47
OR{ (95%CI) 1.00 1.52 (0.61, 3.82) 2.52 (1.03, 6.12) 3.12 (1.31, 7.43) 3.06 (1.25, 7.47) 0.004
3+ years` Cases/Controls 18/54 14/59 21/54 22/51 20/59
OR{ (95%CI) 1.00 0.74 (0.32,1.73) 1.24 (0.58, 2.65) 1.41 (0.66, 2.99) 1.09 (0.48, 2.46) 0.405
{Odds ratios were calculated using conditional logistic regression models with adjustments for BMI, age at menarche, and number of live births.
`For all breast cancer cases, blood samples were collected 3.4 (SD = 2.3) years prior to cancer diagnosis.
doi:10.1371/journal.pone.0065968.t003
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peripheral blood and breast cancer risk. Since mtDNA copy
number is not associated with breast cancer risk among women
who donated a blood sample 3 years prior to their breast cancer
diagnosis and mtDNA copy number decreased with increasing
time interval between dates of blood draw and breast cancer
diagnosis, one possible explanation is that subclinical progression
of breast cancer would have an impact on mtDNA copy number.
The association between altered mtDNA copy in blood samples
collected within 2 years of gastric cancer was also observed in the
Shanghai women’s cohort though in that study lower mtDNA
copy number among participants who donated a blood sample
within 2 years of cancer diagnosis was associated with gastric
cancer risk [16]. These findings further support the idea that both
cancer stage and cancer site may influence mtDNA copy number
in peripheral blood and, in prospective studies, these associations
may be dependent on the timing of blood collection in regards to
cancer diagnosis.
Several studies examined mtDNA copy number in tumor tissues
as well as adjacent normal tissues of various organs. Increased
mtDNA copy number was observed in tumor tissues of the
colorectum [21,22], lung [22], ovary [23], endometrium [24] and
thyroid [25] whereas reduced mtDNA copy number were
observed in tumor tissues of the breast [25,26], stomach [22,27],
liver [22,28] and kidney [29], as compared to their normal
adjacent tissues. These data suggest that the role of tumor mtDNA
in carcinogenesis might be different in different organs or tissue
origin. Reduced mtDNA in tumors has been associated with
somatic mitochondrial mutations [30] and mutations in nuclear
genes such as p53 [31], which occur frequently in breast cancer.
Thus the reduced mtDNA in breast tumors is likely a consequence
of several tumor specific characteristics such as somatic changes in
nuclear and mitochondrial genes and the increased endogenous
oxidative damage observed in breast tumors though the exact
mechanisms still remain incompletely understood [32]. In
addition, reduced mtDNA copy number in breast tumors has
also been associated with increased nuclear damage [33], poorer
overall and disease free survival [30] and better response to
anthracycline based therapy [34] suggesting a functional role for
mitochondrial alterations in breast carcinogenesis. Additional
studies are warranted to elucidate the organ-specific role of
mtDNA in the development of cancer in humans.
The biological mechanism for increased relative mtDNA copy
number in peripheral blood with risk of breast cancer is not
completely understood. Since breast tumor specific mtDNA
mutations have been rarely detected in peripheral blood [35], it
is likely that the contribution of tumor specific mutations in
determining mtDNA copy number in peripheral blood is minimal.
Furthermore, since the correlation between mtDNA copy number
in peripheral blood and breast tissue has not been evaluated in this
study or previous studies, the biological relevance of increased
mtDNA copy number in peripheral blood to breast carcinogenesis
remains unclear. A positive association between the relative
mtDNA copy number and markers of oxidative stress including
thiobarbituric acid reactive substances and 8-hydroxyguanosine
was observed in humans [36]. Lower levels of antioxidants in
plasma were also associated with increased mtDNA copy number
[36]. Fibroblasts that were exposed to mild oxidative stress show
an increase in mitochondrial mass through a cell-cycle indepen-
dent pathway [37]. High relative mtDNA copy number present in
aging cells is thought to be the result of compensatory response to
the cumulative exposures to oxidative stress and cumulative
accumulation of mitochondrial DNA mutations over time [4].
Increased mtDNA copy number in peripheral blood may reflect
increased levels of oxidative damage that has been associated with
breast cancer risk [38,39]. Thus mtDNA copy numbers in breast
tumors and peripheral blood are influenced by biologically distinct
mechanisms and may represent different biological processes that
are relevant to breast carcinogenesis.
The strengths of the current study include comprehensive
recording of breast cancer cases via the Singapore cancer registry
since 1968 [40] and a relatively uniform access to specialized
health care thereby providing complete ascertainment of breast
cancer cases. The study participants originated from two
contiguous regions in South China, leading to a high degree of
genetic homogeneity. All reproductive and lifestyle factors were
assessed prospectively and less likely to be influenced by recall bias.
A relatively large sample size provided sufficient statistical power
(80% power at a=0.05 to detect an odds ratio of 2.0 between the
highest quintile and the lowest quintile of relative mtDNA copy
number) to examine the association between the relative mtDNA
copy number and breast cancer risk. This is the first prospectively
designed study to show a positive association between the relative
mtDNA copy number and risk of breast cancer. Future studies are
warranted to evaluate aging and oxidative stress related factors
that influence mtDNA copy number and to provide novel insights
into biological mechanisms of mtDNA copy number variation on
the development of breast cancer.
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